Drug Therapy Monitoring in Patients with Type 2 Diabetes and Hypertension

The aim of this paper is to detect, prevent and resolve DRP （drug-related problems） and NOM （negative outcomes associated with medication） in hospitalized patients with DM2 （type 2 diabetes） with HTN （hypertension） in a tertiary care clinic. Descriptive cross-sectional interventional study is used. DTM （drug therapy monitoring） was conducted in 73 patients using data obtained from clinical histories and interviews. NOM were detected based on symptoms and laboratory test results. The statistical significance was 0.05. It can be found that 23 DRP were detected, primarily in the category ＂likelihood of adverse effects＂ （30.43%） causing NOM in the ＂non-quantitative safety problem＂ category. The NOM detected were related to safety （62%）, effectiveness （24.5%） and necessity （13.5%）. Of the 68.57% of pharmacist interventions accepted, 48.57% were resolved and 20% were not resolved. A simple linear correlation （r = -0.34） analysis indicated a weak association between patient age and severity ofNOM. DTM made it＇possible to detect suspected DRP and NOM, which were then prevented or resolved, improving the control of HTN and DM2 and helping ensure better drug therapy outcomes for patients.

Interventional therapy for intracranial aneurysms under neuroelectrophysiological monitoring

Objective To study the application of neuroelectrophysiological monitoring for interventional therapy of intracranial aneurysms. Methods 22 patients with intracranial aneurysm underwent neuroelectrophysiological monitoring during interventional therapy. Somatosensory evoked potential( SSEP) ,brainstem

Using fluorodeoxy-D-glucose-positron emission tomography to monitor neoadjuvant chemotherapy response in sarcoma:A meta-analysis

AIM： To systematically evaluate the accuracy of 18-fu-orodeoxy-D-glucose-positron emission tomography （18-FDG PET） to assess response to neoadjuvant che-motherapy in bone and soft tissue sarcomas.METHODS： Studies published in English language re-garding the accuracy of F-18 FDG PET for the indication were retrieved from MEDLINE. The QUADAS tool was utilized for methodological quality appraisal. Relevant data were extracted, and quantitative data synthesis included pooled estimation and subgroup analysis. RESULTS： A total of ffteen studies involving 420 pa-tients with pathologically confrmed sarcoma were col-lected. Methodological quality was relatively high. The pooled sensitivity and specifcity of PET to predict histo-pathological response were 87% （95%CI： 81%-91%） and 83% （95%CI： 77%-87%）, respectively. Ten stud-ies employed a lower standardized uptake value （SUV） after chemotherapies （mostly 2.5） and/or a higher SUV reduction rate （mostly around 50%） as PET criteria of good response. Subgroup analysis showed that PET ex-hibited a signifcantly better specifcity in osteosarcoma （OS） and Ewing sarcoma （ES） than in soft-tissue sarco-ma （STS） （91% vs 75%, P 〈 0.05）, and a higher speci-fcity in pediatric patients than in adults （90% vs 74%, P 〈 0.01）. PET yielded a lower specifcity in ifosfamide-contained chemotherapies than in the alternative regi-men （70% vs 97%, P 〈 0.01）.CONCLUSION： F-18 FDG PET is promising to predict neoadjuvant therapy response in sarcoma, especially in pediatric patients with OS or ES. Certain chemothera-peutic agents could potentially cause false positives of PET.

Photoacoustic imaging of prostate cancer

Photoacoustic imaging(PAI),also known as optoacoustic imaging,is a rapidly growing imaging modality with potential in medical diagnosis and therapy monitoring.This paper focuses on the techniques of prostate PAI and its potential applications in prostate cancer detection.Transurethral light delivery combined with transrectal ultrasound detection overcomes light scattering in the surrounding tissue and provides optimal photoacoustic signals while minimizing invasiveness.While label-free PAI based on endogenous contrast has promising potential for prostate cancer detection,exogenous contrast agents can further enhance the sensitivity and speci¯city of prostate cancer PAI.Further in vivo studies are required in order to achieve the translation of prostate PAI to clinical implementation.The minimal invasiveness,relatively low cost,high speci¯city and sensitivity,and real-time imaging capability are valuable advantages of PAI that may improve the current prostate cancer management in clinic.